{"Title": "FASTlab Radiosynthesis of the 18F-labelled HER2-binding Affibody molecule [18F]GE-226", "Year": 2019, "Source": "J. Label. Compd. Radiopharm.", "Volume": "62", "Issue": 14, "Art.No": null, "PageStart": 925, "PageEnd": 932, "CitedBy": 1, "DOI": "10.1002/jlcr.3789", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85075341795&origin=inward", "Abstract": "\u00a9 2019 John Wiley & Sons, Ltd.An 18F-labelled human epidermal growth factor receptor (HER2) receptor binding radiotracer is a potential tool to non-invasively identify HER2 positive tumour lesions in subjects with recurrent metastatic breast cancer. Having explored the manual radiochemistry to conjugate the Affibody molecule ZHER2:2891 with [18F]4-fluorobenzaldehyde, we have developed and optimised a full protocol for the automated GE FASTlab synthesiser. Our chemometric model predicted the best radiochemical purity for a short conjugation time (2.8 minutes), a low temperature (65\u00b0C), and a medium Affibody molecule precursor amount (5.5 mg). Under these optimised conditions, [18F]GE-226 was produced after solid-phase extraction purification with activity yield of 30% \u00b1 7 (n = 18) and a radiochemical purity of 94% \u00b1 2 (n = 18). The synthesis and purification was complete after 43 minutes and provided apparent molar activities of 12 to 30 GBq/\u03bcmol (n = 12) at the end of synthesis.", "AuthorKeywords": ["Affibody", "Her2", "molecular imaging", "PET diagnostics"], "IndexKeywords": ["Antibodies, Monoclonal", "Chemistry Techniques, Synthetic", "Fluorine Radioisotopes", "Radiochemistry", "Receptor, ErbB-2"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 2, "EID": "2-s2.0-85075341795", "SubjectAreas": [["Analytical Chemistry", "CHEM", "1602"], ["Biochemistry", "BIOC", "1303"], ["Radiology, Nuclear Medicine and Imaging", "MEDI", "2741"], ["Drug Discovery", "PHAR", "3002"], ["Spectroscopy", "CHEM", "1607"], ["Organic Chemistry", "CHEM", "1605"]], "AuthorData": {"56503616100": {"Name": "Iveson P.B.", "AuthorID": "56503616100", "AffiliationID": "60106637", "AffiliationName": "Pharmaceutical Diagnostics, GE Healthcare"}, "7103281884": {"Name": "Glaser M.", "AuthorID": "7103281884", "AffiliationID": "60090043, 60022148", "AffiliationName": "Institute of Nuclear Medicine\u2014Radiochemistry, University College London"}, "57211919140": {"Name": "Shales J.", "AuthorID": "57211919140", "AffiliationID": "60106637", "AffiliationName": "Pharmaceutical Diagnostics, GE Healthcare"}, "35411526400": {"Name": "Luthra S.K.", "AuthorID": "35411526400", "AffiliationID": "60106637", "AffiliationName": "Pharmaceutical Diagnostics, GE Healthcare"}, "56155024300": {"Name": "Hiscock D.", "AuthorID": "56155024300", "AffiliationID": "60106637", "AffiliationName": "Pharmaceutical Diagnostics, GE Healthcare"}, "57188852276": {"Name": "Grigg J.", "AuthorID": "57188852276", "AffiliationID": "60106637", "AffiliationName": "Pharmaceutical Diagnostics, GE Healthcare"}, "6507744150": {"Name": "Indrevoll B.", "AuthorID": "6507744150", "AffiliationID": "60106882", "AffiliationName": "Pharmaceutical Diagnostics, GE Healthcare"}, "57190419138": {"Name": "Mantzilas D.", "AuthorID": "57190419138", "AffiliationID": "60106882", "AffiliationName": "Pharmaceutical Diagnostics, GE Healthcare"}, "57211916070": {"Name": "Omtvedt L.", "AuthorID": "57211916070", "AffiliationID": "60106882", "AffiliationName": "Pharmaceutical Diagnostics, GE Healthcare"}}}